image
Healthcare - Biotechnology - NASDAQ - IL
$ 2.203
-2.95 %
$ 1.88 M
Market Cap
0.92
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one SCNI stock under the worst case scenario is HIDDEN Compared to the current market price of 2.2 USD, Scinai Immunotherapeutics Ltd. is HIDDEN

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one SCNI stock under the base case scenario is HIDDEN Compared to the current market price of 2.2 USD, Scinai Immunotherapeutics Ltd. is HIDDEN

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one SCNI stock under the best case scenario is HIDDEN Compared to the current market price of 2.2 USD, Scinai Immunotherapeutics Ltd. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart SCNI

image
$4.0$4.0$3.5$3.5$3.0$3.0$2.5$2.5$2.0$2.0$1.5$1.515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 JunJul '25Jul '25
FINANCIALS
658 K REVENUE
0.00%
-8.64 M OPERATING INCOME
11.00%
-6.5 M NET INCOME
-12.15%
-9.38 M OPERATING CASH FLOW
-29.14%
-637 K INVESTING CASH FLOW
23.80%
1.09 M FINANCING CASH FLOW
-83.97%
583 K REVENUE
182.99%
-1.2 M OPERATING INCOME
46.80%
10.5 M NET INCOME
551.60%
-2.04 M OPERATING CASH FLOW
-15.93%
-4 K INVESTING CASH FLOW
33.33%
8 K FINANCING CASH FLOW
-33.33%
Balance Sheet Scinai Immunotherapeutics Ltd.
image
Current Assets 5.45 M
Cash & Short-Term Investments 4.87 M
Receivables 366 K
Other Current Assets 211 K
Non-Current Assets 12 M
Long-Term Investments 0
PP&E 12 M
Other Non-Current Assets 0
27.87 %68.82 %Total Assets$17.5m
Current Liabilities 1.78 M
Accounts Payable 535 K
Short-Term Debt 396 K
Other Current Liabilities 849 K
Non-Current Liabilities 20.3 M
Long-Term Debt 20.2 M
Other Non-Current Liabilities 96 K
3.85 %91.49 %Total Liabilities$22.0m
EFFICIENCY
Earnings Waterfall Scinai Immunotherapeutics Ltd.
image
Revenue 658 K
Cost Of Revenue 1.24 M
Gross Profit -580 K
Operating Expenses 8.06 M
Operating Income -8.64 M
Other Expenses -2.14 M
Net Income -6.5 M
1m1m00(1m)(1m)(2m)(2m)(3m)(3m)(4m)(4m)(5m)(5m)(6m)(6m)(7m)(7m)(8m)(8m)(9m)(9m)658k(1m)(580k)(8m)(9m)2m(6m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
-88.15% GROSS MARGIN
-88.15%
-1312.77% OPERATING MARGIN
-1312.77%
728.88% NET MARGIN
728.88%
0.00% ROE
0.00%
0.00% ROA
0.00%
0.00% ROIC
0.00%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Scinai Immunotherapeutics Ltd.
image
00(5m)(5m)(10m)(10m)(15m)(15m)(20m)(20m)(25m)(25m)20152015201620162017201720182018201920192020202020212021202220222023202320242024
Net Income -6.5 M
Depreciation & Amortization 514 K
Capital Expenditures -637 K
Stock-Based Compensation 1.14 M
Change in Working Capital -646 K
Others -4.24 M
Free Cash Flow -10 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Scinai Immunotherapeutics Ltd.
image
SCNI has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
6. Ownership
Insider Ownership Scinai Immunotherapeutics Ltd.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Scinai Highlights New Funding and CDMO Growth Ahead of BIO International Convention 2025 CEO Amir Reichman to meet investors, pharma partners, and CDMO clients at global biotech conference JERUSALEM , June 12, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company developing inflammation and immunology (I&I) therapies and offering biologics CDMO services through its Scinai BioServices unit, today announced CEO Amir Reichman's participation in the BIO International Convention 2025 (June 16–19, Boston). prnewswire.com - 3 weeks ago
Scinai Immunotherapeutics Receives Italian Government Clearance Under Golden Power Regulation for Potential Acquisition of Pincell S.r.l. The regulatory approval marks a key milestone toward the potential acquisition of Pincell, removing a major condition precedent under the option agreement and allowing Scinai to advance toward finalizing the transaction, subject to customary remaining conditions. JERUSALEM , June 5, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. prnewswire.com - 1 month ago
Scinai Reports Q1 2025 Financial Results Highlighting Strong CDMO Revenue Momentum and Reduced Cash Burn JERUSALEM , May 30th, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company focused on developing novel and innovative biological drug candidates for the treatment of inflammation and immunology (I&I) related diseases and on providing CDMO services through its Scinai Bioservices business unit, today announced its financial results for the first three months ended March 31, 2025. prnewswire.com - 1 month ago
Scinai Announces Annual Financial Results for 2024 JERUSALEM , May 7, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company focused on developing novel and innovative biological drug candidates for the treatment of inflammation and immunology (I&I) related diseases and on providing CDMO services through its Scinai Bioservices business unit, today announced its annual financial results for the full year 2024. prnewswire.com - 1 month ago
Scinai Immunotherapeutics and Pincell to Host Webinar on a Blockbuster Drug Candidate for Devastating Rare Skin Diseases The webinar will explore PC111, a novel monoclonal antibody drug candidate with the potential to transform the treatment landscape for Pemphigus Vulgaris and Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN). JERUSALEM, Israel , May 1, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. prnewswire.com - 2 months ago
Scinai signs an option agreement to acquire rare disease company Pincell and its novel antibody for treating Severe Dermatological Conditions Scinai files an application for Euro 12 million grant to fund next stage of development Pincell's monoclonal antibody, PC111, is in development for treating Pemphigus, Steven Johnson's Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) PC111 has already received an Orphan Drug Designation in Pemphigus by the European Medicine's Agency An application will be filed with the FDA for Orphan Drug and Breakthrough Designation in Pemphigus, as well as in SJS/TEN Scinai sees potential for accelerated approval given the severity of these diseases, PC111's innovative, non-immunosuppressive mode of action and the lack of effective alternative treatments JERUSALEM , March 27, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company specializing in inflammation and immunology (I&I) biological products and in providing CDMO services through its Scinai Bioservices unit, today announced that it entered into a binding option agreement for the acquisition of the Italian biotech company Pincell srl. prnewswire.com - 3 months ago
Scinai to Connect with Investors, Showcase its Innovative I&I pipeline and its Boutique cGMP Biologics CDMO during BIO-Europe Spring 2025 JERUSALEM , March 17, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), a biopharmaceutical company specializing in inflammation and immunology (I&I) biological products and in providing CDMO services through its Scinai Bioservices unit, today announced that it will be meeting with investors, showcasing its innovative I&I product pipeline in partnership meetings and exhibiting its CDMO boutique services at the BIO-Europe Spring 2025 conference, taking place March 17-19 in Milan, Italy. prnewswire.com - 3 months ago
SCINAI IMMUNOTHERAPEUTICS ANNOUNCES $10 MILLION STANDBY EQUITY PURCHASE AGREEMENT JERUSALEM , March 5, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai" or the "Company"), a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and providing CDMO services through its Scinai Bioservices business unit, announced that it has entered into a Standby Equity Purchase Agreement (the "SEPA") with YA II PN, Ltd. prnewswire.com - 4 months ago
Scinai to Connect with Investors and Pharma Leaders at Upcoming Key US Conferences JERUSALEM , Jan. 6, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai" or the "Company"), a biopharmaceutical company specializing in inflammation and immunology (I&I) biological products and offering CDMO services through its Scinai Bioservices unit, announced today that its CEO, Mr. prnewswire.com - 5 months ago
Scinai Immunotherapeutics Establishes U.S. Subsidiary for CDMO Business Unit, Scinai Bioservices Inc. JERUSALEM , Dec. 16, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai" or the "Company"), a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and providing CDMO services through its Scinai Bioservices business unit, announced today the establishment of a U.S.-based subsidiary for its Contract Development and Manufacturing Services. prnewswire.com - 6 months ago
Prof. Michael Schön, Director of Dermatology and Venereology at the University Medical Center Göttingen, Germany (UMG), Joins Scinai Immunotherapeutics' Scientific Advisory Board JERUSALEM , Dec. 5, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai" or the "Company"), a biopharmaceutical company specializing in the development of inflammation and immunology (I&I) biological products and offering CDMO services through its Scinai Bioservices unit, announced today the appointment of Prof. prnewswire.com - 7 months ago
Dr. Jonathan Sadeh, Former Senior Vice President of Immunology R&D at Bristol-Myers Squibb, Joins Scinai Immunotherapeutics' Scientific Advisory Board JERUSALEM , Nov. 27, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai" or the "Company"), a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and providing CDMO services through its Scinai Bioservices business unit, announced today that Dr. Jonathan Sadeh has been appointed as a member of the Company's Scientific Advisory Board (SAB). prnewswire.com - 7 months ago
8. Profile Summary

Scinai Immunotherapeutics Ltd. SCNI

image
COUNTRY IL
INDUSTRY Biotechnology
MARKET CAP $ 1.88 M
Dividend Yield 0.00%
Description Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.
Contact Jerusalem BioPark Building, Jerusalem, https://www.scinai.com
IPO Date May 11, 2015
Employees 31
Officers Mr. Amir Reichman M.B.A., M.Sc. Chief Executive Officer & Director Mr. Elad Mark B.Sc., Eng., M.B.A. Chief Operating Officer Ms. Alona Tal Head of Business Administration Mr. Uri Ben-Or CPA, CPA, M.B.A., MBA Chief Financial Officer Merav Kamensky Head of Quality Control Dr. Tamar Ben-Yedidia Ph.D. Chief Scientist Dr. Dalit Weinstein Fischer Ph.D. Chief Technology Officer Dr. Naama Adi Hen Head of Quality Asurance